Frank A. Corvino

460 total citations
25 papers, 356 citations indexed

About

Frank A. Corvino is a scholar working on Oncology, Epidemiology and Hematology. According to data from OpenAlex, Frank A. Corvino has authored 25 papers receiving a total of 356 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 5 papers in Epidemiology and 5 papers in Hematology. Recurrent topics in Frank A. Corvino's work include Pancreatic and Hepatic Oncology Research (5 papers), Lung Cancer Treatments and Mutations (4 papers) and Lung Cancer Research Studies (3 papers). Frank A. Corvino is often cited by papers focused on Pancreatic and Hepatic Oncology Research (5 papers), Lung Cancer Treatments and Mutations (4 papers) and Lung Cancer Research Studies (3 papers). Frank A. Corvino collaborates with scholars based in United States, Germany and Japan. Frank A. Corvino's co-authors include Florent Richy, Ulrike Gottwald‐Hostalek, Andy Surinach, Sumit Mohan, Weiying Wang, G. Binder, Steven R. Arikian, S. Ali Husain, Tracy J. Mayne and Kristen L. King and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Diabetes Care.

In The Last Decade

Frank A. Corvino

25 papers receiving 348 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Frank A. Corvino United States 10 84 83 75 74 66 25 356
Ana Huerta Spain 14 57 0.7× 42 0.5× 46 0.6× 68 0.9× 107 1.6× 40 489
Özlem Harmankaya Türkiye 12 77 0.9× 75 0.9× 37 0.5× 68 0.9× 61 0.9× 41 454
Irma Matinlauri Finland 14 101 1.2× 154 1.9× 46 0.6× 42 0.6× 119 1.8× 34 536
Maïté Jaureguy France 10 70 0.8× 68 0.8× 13 0.2× 50 0.7× 70 1.1× 22 404
Robert B. Huizinga United States 12 44 0.5× 44 0.5× 20 0.3× 52 0.7× 43 0.7× 33 709
Thomas Vanhove Belgium 13 197 2.3× 85 1.0× 31 0.4× 58 0.8× 91 1.4× 24 678
Jean-Christophe Szelag France 9 88 1.0× 94 1.1× 21 0.3× 53 0.7× 147 2.2× 15 652
Manuel Arias Spain 13 195 2.3× 71 0.9× 32 0.4× 35 0.5× 82 1.2× 21 664
Christophe Gerbeau Switzerland 12 123 1.5× 46 0.6× 47 0.6× 50 0.7× 166 2.5× 27 498
Christopher Clardy United States 10 84 1.0× 46 0.6× 10 0.1× 95 1.3× 61 0.9× 17 405

Countries citing papers authored by Frank A. Corvino

Since Specialization
Citations

This map shows the geographic impact of Frank A. Corvino's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank A. Corvino with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank A. Corvino more than expected).

Fields of papers citing papers by Frank A. Corvino

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank A. Corvino. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank A. Corvino. The network helps show where Frank A. Corvino may publish in the future.

Co-authorship network of co-authors of Frank A. Corvino

This figure shows the co-authorship network connecting the top 25 collaborators of Frank A. Corvino. A scholar is included among the top collaborators of Frank A. Corvino based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frank A. Corvino. Frank A. Corvino is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schold, Jesse D., Robert J. Nordyke, Zheng Wu, et al.. (2022). Clinical Events and Renal Function in the First Year Predict Long-Term Kidney Transplant Survival. Kidney360. 3(4). 714–727. 10 indexed citations
2.
Kim, George P., Andy Surinach, Frank A. Corvino, et al.. (2020). Real-World Outcomes Associated with Liposomal Irinotecan Dose Reductions in Metastatic Pancreatic Ductal Adenocarcinoma. Future Oncology. 17(6). 675–688. 9 indexed citations
3.
Barzi, Afsaneh, Rebecca A. Miksad, Andy Surinach, et al.. (2020). Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States. Pancreas. 49(2). 193–200. 25 indexed citations
4.
5.
Burudpakdee, Chakkarin, et al.. (2018). Economic impact of preventing brain metastases with alectinib in ALK-positive non-small cell lung cancer. Lung Cancer. 119. 103–111. 26 indexed citations
6.
Barzi, Afsaneh, Rebecca A. Miksad, Andy Surinach, et al.. (2018). Real world outcomes of metastatic pancreatic cancer (mPC) patients (pts) treated with liposomal irinotecan (nal-IRI) in the US.. Journal of Clinical Oncology. 36(15_suppl). e16229–e16229. 2 indexed citations
7.
Lodise, Thomas P., Roger Echols, Weiying Wang, Frank A. Corvino, & Bin Cai. (2018). 1191. Prevalence and Microbiology of Carbapenem Resistance Among Six Gram-Negative Pathogens in Bloodstream Infections in US Hospitals, 2010–2015. Open Forum Infectious Diseases. 5(suppl_1). S360–S360. 2 indexed citations
8.
Gluck, Eric H., et al.. (2018). Real-world use of procalcitonin and other biomarkers among sepsis hospitalizations in the United States: A retrospective, observational study. PLoS ONE. 13(10). e0205924–e0205924. 21 indexed citations
9.
Corvino, Frank A., et al.. (2018). Anaphylaxis care guidelines and the effect on health care resource use in the United States. Annals of Allergy Asthma & Immunology. 121(1). 132–134.e3. 2 indexed citations
10.
Ahn, Dae‐Ro, Afsaneh Barzi, Rebecca A. Miksad, et al.. (2018). Real-world dosing patterns of patients (pts) with metastatic pancreatic cancer (mPC) treated with liposomal irinotecan (nal-IRI) in US oncology clinics. Annals of Oncology. 29. viii251–viii251. 1 indexed citations
11.
12.
Corvino, Frank A., et al.. (2017). The association of timing of disease-modifying drug initiation and relapse in patients with multiple sclerosis using electronic health records. Current Medical Research and Opinion. 33(6). 1127–1132. 5 indexed citations
13.
Corvino, Frank A., et al.. (2017). P3.01-086 Biomarker Testing Trends and Treatment Patterns in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients in the United States. Journal of Thoracic Oncology. 12(11). S2235–S2236. 1 indexed citations
14.
Reveles, Kelly R., et al.. (2017). Fidaxomicin versus Vancomycin as a First‐Line Treatment for Clostridium difficile–Associated Diarrhea in Specific Patient Populations: A Pharmacoeconomic Evaluation. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 37(12). 1489–1497. 16 indexed citations
15.
Smith, B. Douglas, Amy E. DeZern, G. Binder, et al.. (2016). Patterns of total cost for patients (pts) with active treatment (Tx) of myelodysplastic syndromes (MDS).. Journal of Clinical Oncology. 34(15_suppl). e18252–e18252. 1 indexed citations
16.
17.
Smith, Meredith Y., et al.. (2015). Postmarketing Safety Profile of Subcutaneous Interferon Beta-1a Given 3 Times Weekly: A Retrospective Administrative Claims Analysis. Journal of Managed Care & Specialty Pharmacy. 21(8). 650–660. 17 indexed citations
18.
19.
Fessatidis, Vassilios, et al.. (2010). Analytic properties of moments matrices. Physics Letters A. 374(28). 2890–2893. 4 indexed citations
20.
Corvino, Frank A.. (2005). Standards for satisfaction.. PubMed. 25(2). 45–7. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ana Huerta Breakdown of academic impact, for papers by Özlem Harmankaya Breakdown of academic impact, for papers by Irma Matinlauri Breakdown of academic impact, for papers by Maïté Jaureguy Breakdown of academic impact, for papers by Robert B. Huizinga Breakdown of academic impact, for papers by Thomas Vanhove Breakdown of academic impact, for papers by Jean-Christophe Szelag Breakdown of academic impact, for papers by Manuel Arias Breakdown of academic impact, for papers by Christophe Gerbeau Breakdown of academic impact, for papers by Christopher Clardy
Rankless by CCL
2026